ksoulstring

About Kenny Soulstring

Kenny Soulstring is an entrepreneurial visionary with a thirty year history developing and operating small to mid sized businesses. His experience in building a brand led to his interest in investing in small and emerging companies, and for the prior twenty years, his investments allow him to take part in new ventures without undertaking all of the legwork. Focused on finding compelling opportunities in the small cap sector, Soulstring enjoys the art of the build, watching a company develop from concept to maturity. His frequent contact with company management allows him to offer timely and relevant information, working to keep news fresh with a spicy commentary to match. Soulstring was raised in Miami Beach, Florida and plans to retire there when his hair turns fully gray.
Pareteum (TEUM) Stock: Making the Cloud Accessible to Every Person and Every Thing
  • Pareteum (TEUM) Stock: Making the Cloud Accessible to Every Person and Every Thing

Pareteum (TEUM) Stock: Making the Cloud Accessible to Every Person and Every Thing

By |February 13th, 2018|

In a technologically driven world, interconnectivity has become the name of the game for businesses looking to streamline company operations and maximize revenues. From laptops to mobile phones, and anything else that comprises the “Internet of Things”, the ability to seamlessly access data anywhere and at any time is an invaluable component of any […]

Stater and Long Blockchain (LBCC) Stock: "Real" Disruption In The Cryptocurrency And Forex Trading Landscape
  • Stater and Long Blockchain (LBCC) Stock: "Real" Disruption In The Cryptocurrency And Forex Trading Landscape

Stater and Long Blockchain (LBCC) Stock: “Real” Disruption in the Cryptocurrency and Forex Trading Landscape

By |January 23rd, 2018|

LBCC investors preparing to see huge upside from Stater Blockchain Acquisition and spin out of Long Island Brands.
Investors are going mad over anything “crypto.” So much so, in fact, that their mission to find legitimate investment opportunity is getting replaced with cleverly written promotional hype. For instance, in the United States, a large handful […]

Aytu Bioscience (AYTU) Stock: Gets a Boost on Delays for Antares Pharma's, Xyosted™
  • Aytu Bioscience (AYTU) Stock: Gets a Boost on Delays for Antares Pharma's, Xyosted™

Aytu Bioscience (AYTU) Stock: Gets a Boost on Delays for Antares Pharma’s, Xyosted™

By |January 23rd, 2018|

For Aytu Bioscience and its leading low-T product, Natesto®, the good news keeps coming. Since the beginning of the year, two of Natesto®’s most advanced clinical stage competitors got handed significant FDA Advisory Committee setbacks, with both Lipocine’s (NASDAQ: LPCN) TLANDO® and privately held Clarus Therapeutics’ Jatenzo®, getting tagged with negative panel reviews and […]

Aytu BioScience Gets A Double Bonus From TLANDO® and Jatenzo® Misses
  • Aytu BioScience Gets A Double Bonus From TLANDO® and Jatenzo® Misses

Aytu BioScience Gets A Double Bonus From TLANDO® and Jatenzo® Misses

By |January 17th, 2018|

Catching emerging biotech stocks at their low’s isn’t necessarily difficult, but it does take a willingness to look at the derivatives that make up the whole when analyzing the opportunity. Those that are following Aytu BioScience (NasdaqCM: AYTU) are well aware of the company’s impressive growth in new prescription rates from Natesto®, the company’s […]

FTE Networks (FTNW) Stock: Connects For Explosive Growth In 2018
  • FTE Networks (FTNW) Stock: Connects For Explosive Growth In 2018

FTE Networks (FTNW) Stock: Connects For Explosive Growth In 2018

By |January 17th, 2018|

As we enter the final two years of this technologically powered decade, it is more evident than ever that high-quality wireless connectivity and its accompanying infrastructure solutions are a competitive necessity for profit-minded and service-oriented companies. And, at the risk of sounding overly simplistic, a fast and reliable networking infrastructure can significantly augment a […]

Aytu BioScience (AYTU) Stock: Why 2018 May Be The  Breakthrough Year
  • Aytu BioScience (AYTU) Stock: Why 2018 May Be The  Breakthrough Year

Aytu BioScience (AYTU) Stock: Why 2018 May Be The  Breakthrough Year

By |January 16th, 2018|

As the media tends to focus on the activities played out by Big Pharma, it can be easy for investors to overlook the exciting and often revolutionary developments that are happening at niche pharmaceutical companies. Small pharmaceutical companies can be a lucrative prospect for investors, as the niche markets they target usually allow for […]

Aytu BioScience Pushes Natesto® Sales to New Record High
  • Aytu BioScience Pushes Natesto® Sales to New Record High

Aytu BioScience Pushes Natesto® Sales to New Record High

By |December 6th, 2017|

Aytu BioScience on Tuesday of last week again reported record prescription sales for Natesto®, its FDA-approved nasally administered testosterone replacement therapy. Sales for October reached 827 total prescriptions, representing a 17% increase over September totals. Additionally, new prescriptions, as well as the number of new prescribers, which provides the most current and accurate gauge […]

Milestone Scientific (MLSS) Stock: A Compelling Opportunity In A Vast Market
  • Milestone Scientific (MLSS) Stock: A Compelling Opportunity In A Vast Market

Milestone Scientific (MLSS) Stock: A Compelling Opportunity In A Vast Market

By |November 15th, 2017|

The biotechnology industry is one that is booming with innovation. Cures for some of the world’s most devastating illnesses have been and continue to be invented, new technologies are providing physicians with less invasive and more effective options for treating their patients, and breakthroughs in just about every aspect of the industry are taking […]

Aytu Bioscience (AYTU) Stock: With Multiple Catalysts Posted, Share Price Is Ridiculously Low
  • Aytu Bioscience (AYTU) Stock: With Multiple Catalysts Posted, Share Price Is Ridiculously Low

Aytu Bioscience (AYTU) Stock: With Multiple Catalysts Posted, Share Price Is Ridiculously Low

By |November 8th, 2017|

Many people follow the age-old adage to forget half of what you read and most of what you hear. And, no matter what side of that spectrum that you reside on, there can be little dispute that the media will report on stories that best fit their customer demographic. Well, likewise – when it […]

AIT Therapeutics (AITB) Stock: Positioned To Propel Nitric Oxide Treatment Into The Mainstream
  • AIT Therapeutics (AITB) Stock: Positioned To Propel Nitric Oxide Treatment Into The Mainstream

AIT Therapeutics (AITB) Stock: Positioned To Propel Nitric Oxide Treatment Into The Mainstream

By |November 8th, 2017|

Investors, if you have not yet met AIT Therapeutics (AITB), consider yourself privileged to be provided an introduction. Now, although that prior statement may read as presumptuous, once investors get initiated to the premise that AITB sits ideally positioned to alter the therapeutic landscape for treating respiratory infection and pulmonary hypertension, the favorable opinion […]